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We sought to determine if autologous umbilical cord blood (UCB) infusion followed by 1 year of supple-
mentation with vitamin D and docosahexaenoic acid (DHA) can preserve C-peptide in children with type 1
diabetes. We conducted an open-label, 2:1 randomized study in which 15 type 1 diabetes subjects with
stimulated C-peptide > .2 pmol/mL received either (1) autologous UCB infusion, 1 year of daily oral vitamin D
(2000 IU), and DHA (38 mg/kg) and intensive diabetes management or (2) intensive diabetes management
alone. Primary analyses were performed 1 year after UCB infusion. Treated (N ¼ 10) and control (N ¼ 5)
subjects had median ages of 7.2 and 6.6 years, respectively. No severe adverse events were observed.
Although the absolute rate of C-peptide decline was slower in treated versus control subjects, intergroup
comparisons failed to reach signiﬁcance (P ¼ .29). Area under the curve C-peptide declined and insulin use
increased in both groups (P < .01). Vitamin D levels remained stable in treated subjects but declined in control
subjects (P ¼ .01). DHA levels rose in treated subjects versus control subjects (P ¼ .003). CD4/CD8 ratio
remained stable in treated subjects but declined in control subjects (P ¼ .03). No changes were seen in
regulatory T cell frequency, total CD4 counts, or autoantibody titers. Autologous UCB infusion followed by
daily supplementation with vitamin D and DHAwas safe but failed to preserve C-peptide. Lack of signiﬁcance
may reﬂect small sample size. Future efforts will require expansion of speciﬁc immunoregulatory cell subsets,
optimization of combined immunoregulatory and anti-inﬂammatory agents, and larger study cohorts.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION development of low-risk (ie, safe) therapies for young chil-
We previously investigated the potential for a single
autologous umbilical cord blood (UCB) infusion to augment
the natural history of type 1 diabetes in very young children
[1-4]. Although our initial effort was not powered to
demonstrate efﬁcacy, the apparent safety of autologous UCB
infusion as well as the observed postinfusion increase in
peripheral blood regulatory T cell (Treg) frequency provided
impetus for additional studies. Given our group’s emphasis
on the potential for combination therapies to provide
synergy in attenuating autoimmunity and facilitating thedren with type 1 diabetes, we hypothesized that autologous
UCB therapy could be successfully augmented by the addi-
tion of two agents with well-characterized immunomodu-
latory properties and potential links to type 1 diabetes
pathophysiology, namely, vitamin D and docosahexaenoic
acid (DHA) [5,6]. As such, we sought to perform a follow-up
pilot study using this combination approach to document
safety and feasibility and to generate data to guide future
fully powered studies using autologous cell therapies.
METHODS
Participants
Children with type 1 diabetes older than 1 year of age and for whom
autologous UCB was stored were recruited for participation (NCT00873925;
FDA IND BB-11918).
Procedures
Potential subjects underwent a baseline 2-hour mixed meal tolerance
test to determine eligibility [1]. Subjects with peak C-peptide > .2 pmol/L
were randomized 2:1 (treatment-to-control) in an open-label manner. All
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M.J. Haller et al. / Biol Blood Marrow Transplant 19 (2013) 1124e1135 1127subjects had blood drawn at baseline for complete blood count, BMP, HbA1c,
beta cell autoantibodies, vitamin D studies, serum cytokines, and ﬂow
cytometrywith staining forCD3, CD4, CD8, CD25, CD62L, CD45RA, andFOXP3
performed as previously described [2]. Lipid fractions were obtained from
whole blood by amodiﬁcation of Bligh and Dyer [7]. Fatty acids present were
converted to methyl esters [8] and analyzed by gas chromatography (model
HP6890;Hewlett-Packard,Wilmington,DE) using aCP-WAXcolumn (Varian,
Walnut Creek, CA) with mass spectral detection in electron impact mode.
Subjects randomized to therapy had peripheral blood and an aliquot
of UCB shipped to the University of Florida for infectious disease testing,
HLA conﬁrmation, and viability screening. Thereafter, the UCB unit of
qualiﬁed subjects was shipped to the University of Florida and stored until
infusion. A detailed description of our UCB infusion protocol was previously
published [1].
Subjects received pretreatment with diphenhydramine and acetamin-
ophen. No other preparative therapy was given. Thawed UCB cells were
infused through a peripheral intravenous line over 10 to 20 minutes After
UCB infusion, subjects randomized to treatment began a regimen of oral
vitamin D (2000 IU/day), given as 1 drop of vitamin D3 (2000 IU per
drop; Carlson Laboratories, Woodbridge, Ontario, Canada), and oral DHA
(38 mg/kg/day) given as 200-mg gel caps (Martek Biosciences Corporation,
Columbia, MD). All subjects returned for follow-up testing (identical to
baseline) at 3 months, 6 months, and 1 year.
Statistical Analysis
Because outliers in some variables were expected, nonparametric
methods were used for all analyses. Because this is a pilot trial, where Type II
errors are as serious as Type I errors, no control for study-wide Type I error
was made. Within each treatment group, comparisons for changes from
baseline with month 12 were performed via the two-sided Wilcoxon signed
rank test. Comparisons for between-treatment changes from baseline with
month 12 were performed via the two-sample, two-sided Wilcoxon rank
test. Descriptive statistics are given as median (50th percentile) and quar-
tiles (25th and 75th percentile). Sample sizes were not based on a power
computation but on constraints of funding and subject availability. For
descriptive purposes, P < .05 was considered to be signiﬁcant, but actual
P values are provided.RESULTS
Baseline and longitudinal postinfusion characteristics for
all subjects are provided in Table 1. Between April 22, 2009
and August 31, 2010, 15 eligible childrenwith type 1 diabetes
were randomized (10 treated and 5 control subjects). Five
control subjects (3 boys), median age 6.6 years, received
intensive diabetes management alone. Ten treated subjects
(8 boys), median age 7.2 years, received a single autologous
UCB transfusion. All aliquots of UCB had negative Gram
stains, and none grew pathogenic organisms when cultured
for virus, bacteria, or fungus. One subject developed a cough
during infusion that was assessed as a mild infusion reaction
and was treated with 20 mg i.v. diphenhydramine. No other
adverse events were observed in associationwith autologous
UCB infusion.
Median time from diagnosis to screening was 119 days in
the 10 treated children and 106 days in the 5 control subjects.
The median infused total nucleated cell count was 1.1  107
cells/kg (0.4  107 and 3.9  107, respectively; N ¼ 10).
Median viability was 92.5% (90% and 98%, respectively; N ¼
10). After UCB infusion, subjects randomized to treatment
received 1 year of daily oral supplementation with DHA (38
mg/kg/day) and vitamin D (2000 IU/day). Based on capsule
counts, DHA compliance was estimated at 91%.
HbA1c remained statistically unchanged (P ¼ .4) in both
groups throughout the study, with excellent control evi-
denced by the mean HbA1c of 7.3% at the 1-year visit. Insulin
requirements increased signiﬁcantly in both groups (P ¼
.001), although they did not differ signiﬁcantly when per-
forming between-group comparisons (P ¼ .18).
Among treated subjects, area under the curve (AUC)
C-peptide at the time of UCB infusion was 0.30 pmol/mL per
120 minutes (interquartile ratio), whereas control subjects
M.J. Haller et al. / Biol Blood Marrow Transplant 19 (2013) 1124e11351128demonstrated baseline AUC C-peptide of 0.55 pmol/mL per
120 minutes. AUC C-peptide declined at all subsequent study
visits for both groups compared with baseline (P < .01,
baseline to 1 year) (Table 1). In addition, although the
absolute rate of C-peptide decline was slower in treated
(0.23 pmol/mL per 120 minutes) versus control subjects
(0.33 pmol/mL per 120 minutes), differences in change of
AUC C-peptide between treated and control subjects did not
reach signiﬁcance at 1 year (P ¼ .29). Peak C-peptide data
demonstrated a similar pattern (Table 1).
When compared with baseline, vitamin D levels were not
statistically different at 1 year when evaluating patients who
received vitamin D supplementation. However, control
subjects demonstrated signiﬁcant declines in vitamin D
levels (P ¼ .05), and the intergroup comparison was also
signiﬁcant (P ¼ .01).
Fatty acid analysis revealed signiﬁcant increases among
treated subjects treated with DHA (P ¼ .01), docosapentae-
noic acid (P¼ .009), and eicosapentaenoic acid (P¼ .01) when
compared with control subjects. No signiﬁcant changes were
observed in Treg frequency, CD4/CD8 ratio (Table 1), or
cytokines and beta cell autoantibodies (data not shown).DISCUSSION
In contrast to our initial studies of autologous UCB therapy
in patients with type 1 diabetes, this protocol required that
subjects demonstrate mixed meal tolerance testestimulated
C-peptide >.2 pmol/L. Despite the requirement for (at least
minimal) endogenous beta cell function, the small sample
size in this follow-up pilot study limited our capacity to
demonstrate C-peptide preservation after combination
therapy with autologous UCB, vitamin D, and DHA.
In addition to the limitation imparted by the relatively
small number of study subjects, the capacity to preserve beta
cell function may actually be limited by a number of factors.
First, an insufﬁcient number of cells that carried regenerative
or immunoregulatory capacity may have been transferred to
patients with type 1 diabetes. Second, the ongoing autoim-
mune response in subjects with new-onset type 1 diabetes
may contain memory T cells, which are refractive to regula-
tion by Tregs [9], that facilitate the ongoing autoimmune
destruction of endogenous or de novo beta cells. Third,
vitamin D and DHA, chosen as adjunct therapies largely
because of their very-low-risk proﬁles, may lack the immu-
nomodulatory capacity to provide meaningful treatment in
the face of a well-established autoimmune attack.
To address the ﬁrst issue, efforts are underway to isolate
and expand speciﬁc cell populations within UCB to augment
their therapeutic potential. As proof of concept, a phase I
clinical trial is currently underway in adult patients with
recent-onset type 1 diabetes using autologous expanded
Tregs isolated from peripheral blood (NCT01210664). In
terms of the second and third limitations, studies from our
laboratory suggest that a therapeutic approach involving
transient immune depletion and subsequent induction of
immune regulation using a combination of low-dose thy-
moglobulin and pegylated granulocyte colony-stimulating
factor is optimal [10]. As such, we believe that therapies
combining transient immune depletion (using thymoglobu-
lin or similar agents) and subsequent infusion of expanded
UCB Tregs with or without additional stem cell mobilizing
agents may more effectively reset the balance of regulatory
and effector T cells in type 1 diabetes. Such approaches will
undoubtedly require ongoing discussion regarding equipoisewhen being considered as options for the treatment of type 1
diabetes in young children.
Although the combination of UCB infusion, vitamin D, and
DHA did not demonstrate C-peptide preservation in this
underpowered study, the potential of UCB to participate as
a meaningful component in type 1 diabetes intervention
therapies remains. Given the very small sample size used in
this pilot study, we must be careful to avoid the assumption
that a lack of statistical signiﬁcance implies that cord blood
therapies are incapable of providing beneﬁt in type 1 dia-
betes. Indeed, as rates for autologous cord blood banking
climb, we suspect that larger studies can and should follow
our efforts. Strong scientiﬁc rationale for autologous UCB
therapies remains. As such, additional efforts to use autolo-
gous UCB in the treatment of type 1 diabetes will continue,
with emphasis on improved understanding of UCB Treg
function and the potential use of expanded autologous UCB
Tregs either alone or in combination with other immuno-
modulatory agents.
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The optimal therapy for steroid-refractory (SR) acute graft-versus-host disease (aGVHD) is undeﬁned. We
studied patients with SR aGVHD, comparing extracorporeal photopheresis (ECP; n ¼ 57) and anticytokine
therapy (n ¼ 41). In multivariate analyses, ECP, adjusted for steroid dose (odds ratio, 3.42; P ¼ .007), and grade
>II aGVHD (odds ratio, 68; P < .001) were independent predictors of response. ECP therapy, adjusted for
conditioning regimen intensity and steroid dose, was associated with superior survival (hazard ratio [HR], 4.6;
P ¼ .016) in patients with SR grade II aGVHD. Grade >II aGVHD at onset of salvage therapy (HR, 9.4; P < .001)
and lack of response to therapy (HR, 3.09; P ¼ .011) were associated with inferior survival. These ﬁndings
require validation in a prospective randomized study.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION for SR aGVHD [10-12]. The outcomes of ECP and anticytokine
Graft-versus-host disease (GVHD) remains an important
complication of allogeneic stem cell transplantation (allo-
SCT). Despite prophylaxis, International Bone Marrow Trans-
plantation Registry severity index grade B-D acute GVHD
(aGVHD) occurs in 39%-59% of patients undergoing T
cellereplete related or unrelated donor allo-SCT [1]. Cortico-
steroids are the cornerstone of initial therapy for grade II or
grade B-D aGVHD [2-4], leading to complete response (CR) in
25%-69% of patients [5,6]. Patients not responding to steroids
have a dismal prognosis, with poor survival [2,7].
Numerous agents for treating steroid-refractory (SR)
aGVHD have been studied [7,8]. The French group published
its experience in a cohort of 93 patients with SR aGVHD using
either inolimumab or etanercept [9]. Single-center studies
have suggested extracorporeal photopheresis (ECP) using
UV-A irradiation of peripheral blood mononuclear cells after
incubation with 8-methoxypsoralen as effective treatmenttherapy have not been compared previously. In the present
study, we performed a retrospective comparison of the efﬁ-
cacy of second-line therapy in 98 patients treatedwith either
ECP (n ¼ 57) or anticytokine therapy (n ¼ 41).
METHODS
Consecutive patients undergoing allo-SCT after January 2005 and devel-
oping grade II (according to modiﬁed Glucksberg criteria [13]) SR aGVHD
(deﬁned as progression after 3 days or no response after 7 days of initial
therapy) and treatedwith ECP (Nashville, Tennessee, USA, n¼ 13;Nottingham,
UK, n¼ 19; Vienna, Austria, n¼ 25) orwith anticytokine therapy (Paris, France,
n¼ 41)were included. Other inclusion criteriawere corticosteroids at a dose of
least1mg/kg/day alone as ﬁrst-line therapy for aGVHDwith continuation of
calcineurin inhibitors. Anticytokine therapy consisted of inolimumab or eta-
nercept (after 2003). Given that the ECP cohort was recruited after 2005, only
a subsetofpatients fromtheFrenchdataset (41patientswithSRaGVHDtreated
with inolimumaboretanercept after 2005)was included in the non-ECP group
[9]. ECPwas initiated at a frequency of 2-3 treatments per week on aweekly or
biweekly basis. ECP therapywas stopped aftermaximal responsewas achieved
(Austria and UK) or was tapered gradually (Tennessee, USA).
Response was deﬁned as CR (disappearance of signs of GVHD from all
organs involved), partial response (PR; any improvement in GVHD), or
progressive disease (no response or worsening of GVHD in at least 1 organ).
The use of additional immunosuppressive agents after ECP or anticytokine
therapy for controlling aGVHD was considered progressive disease.
Response was assessed at 4 weeks after anticytokine therapy or at the end of
ECP (a median of 45 days after the start of ECP). Given the variability of
response assessment and retrospective nature of the analyses, the primary
focus of this analysis was overall survival (OS).
Descriptive statistics were calculated and groups were compared using
the chi-squared test (nominal) and Wilcoxon rank-sum test (continuous)
respectively. Two-proportion tests were used to compare stage of GVHD
before and after therapy. OS was measured from the initiation of ECP or
anticytokine therapy using Kaplan-Meier survival curves and compared
